DAREON®-NEC-1: Phase III trial of first-line obrixtamig plus SoC in patients with DLL3-positive epNEC (NCT07544654)

DAREON®-NEC-1: A Phase III, multi-center, open-label, randomized, controlled trial of intravenous obrixtamig in combination with carboplatin and etoposide vs. carboplatin and etoposide as first-line therapy in DLL3-positive patients with unresectable locally advanced or metastatic extrapulmonary neuroendocrine carcinomas¹

*DLL3 testing was performed using an investigational antibody for DLL3 (SP347; Roche Diagnostics).
DC, disease control; DLL3, delta-like ligand 3; DoR, duration of response; ECOG PS, Eastern Cooperative Oncology Group performance status; epNEC, extrapulmonary neuroendocrine carcinoma; OR, objective response; OS, overall survival; PFS, progression-free survival; PRO, patient reported outcome; SoC, standard of care